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Plant-Made Oral Vaccines Against Human Infectious Diseases—Are we There
yet?
Abstract
Although the plant-made vaccine field started three decades ago with the promise of developing low-cost
vaccines to prevent infectious disease outbreaks and epidemics around the globe, this goal has not yet
been achieved. Plants offer several major advantages in vaccine generation, including low-cost
production by eliminating expensive fermentation and purification systems, sterile delivery and cold
storage/transportation. Most importantly, oral vaccination using plant-made antigens confers both
mucosal (IgA) and systemic (IgG) immunity. Studies in the past 5 years have made significant progress in
expressing vaccine antigens in edible leaves (especially lettuce), processing leaves or seeds through
lyophilization and achieving antigen stability and efficacy after prolonged storage at ambient
temperatures. Bioencapsulation of antigens in plant cells protects them from the digestive system; the
fusion of antigens to transmucosal carriers enhances efficiency of their delivery to the immune system
and facilitates successful development of plant vaccines as oral boosters. However, the lack of oral
priming approaches diminishes these advantages because purified antigens, cold storage/transportation
and limited shelf life are still major challenges for priming with adjuvants and for antigen delivery by
injection. Yet another challenge is the risk of inducing tolerance without priming the host immune system.
Therefore, mechanistic aspects of these two opposing processes (antibody production or suppression)
are discussed in this review. In addition, we summarize recent progress made in oral delivery of vaccine
antigens expressed in plant cells via the chloroplast or nuclear genomes and potential challenges in
achieving immunity against infectious diseases using cold-chain-free vaccine delivery approaches.
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Summary
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Although the plant-made vaccine field started three decades ago with the promise of developing
low-cost vaccines to prevent infectious disease outbreaks and epidemics around the globe, this
goal has not yet been achieved. Plants offer several major advantages in vaccine generation,
including low-cost production by eliminating expensive fermentation and purification systems,
sterile delivery and cold storage/transportation. Most importantly, oral vaccination using plantmade antigens confers both mucosal (IgA) and systemic (IgG) immunity. Studies in the past 5
years have made significant progress in expressing vaccine antigens in edible leaves (especially
lettuce), processing leaves or seeds through lyophilization and achieving antigen stability and
efficacy after prolonged storage at ambient temperatures. Bioencapsulation of antigens in plant
cells protects them from the digestive system; the fusion of antigens to transmucosal carriers
enhances efficiency of their delivery to the immune system and facilitates successful development
of plant vaccines as oral boosters. However, the lack of oral priming approaches diminishes these
advantages because purified antigens, cold storage/transportation and limited shelf life are still
major challenges for priming with adjuvants and for antigen delivery by injection. Yet another
challenge is the risk of inducing tolerance without priming the host immune system. Therefore,
mechanistic aspects of these two opposing processes (antibody production or suppression) are
discussed in this review. In addition, we summarize recent progress made in oral delivery of
vaccine antigens expressed in plant cells via the chloroplast or nuclear genomes and potential
challenges in achieving immunity against infectious diseases using cold-chain-free vaccine
delivery approaches.
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Traditional vaccines consist of inactivated or attenuated pathogens and are not entirely safe.
Vaccine-derived poliovirus has been reported in a number of countries (Wang et al., 2014).
Live attenuated and killed viruses carry the risk of reverting to virulence, as well as other
drawbacks in terms of antigenic variability between species, low levels of immunogenicity
and possible gene transfer to wild-type strains (Adeniji and Faleye, 2015; Burns et al.,
2014). An outbreak of type 2 vaccine-derived polio in Nigeria was first detected in 2006,
became endemic in Africa and persists today (Famulare and Hu, 2015). This large
poliomyelitis outbreak, caused by type 2 circulating vaccine-derived poliovirus (cVDPV2),
began in 2005 in northern Nigeria. According to the phylogenetic analysis of the P1/capsid
region sequences of isolates from the 403 cases reported between 2005 and 2011, at least 7
of 23 independent type 2 vaccine-derived poliovirus (VDPV2) emergences established
circulating lineage groups (Burns et al., 2013). Therefore, new approaches are needed to
improve current vaccines.

Author Manuscript

Plant-made subunit vaccines are heat stable, lack animal pathogen contamination and can be
engineered to contain multiple antigens, such as those that are combined with subunits of
cholera toxin (CT), for the protection of humans and animals against multiple infectious
diseases (Davoodi-Semiromi et al., 2010; Hefferon, 2013; Kwon et al., 2013b; Scotti et al.,
2010). It is possible to harvest and process plant material on a large scale. When plants
expressing a recombinant antigen are used as feed, they eliminate the purification
requirement (Peters and Stoger, 2011). Plants offer general advantages for large-scale
economic production, product safety and ease of storage and distribution (Holásková et al.,
2015). Plant-based oral vaccines could revolutionize the vaccine industry by reducing the
cost of complex production systems, such as fermentation, purification, cold storage and
transportation (Kwon et al., 2013b). In addition, the use of plants to express pathogen
subunit vaccine proteins allows the rapid production of diverse antigens that contain
disulphide bonds, are glycosylated or require other post-translational modifications to
achieve their desired biological function (Kwon et al., 2013b; Yusibov et al., 2011). The use
of transgenic plants to produce subunit vaccine proteins has been developed as an alternative
platform for the large-scale production and delivery of vaccines to induce protective
immune responses via the mucosal immune system (Daniell et al., 2009). Vegetable and
fruit crops are ideal host systems for oral vaccine production. Potential plant species used for
pharmaceutical protein production include alfalfa, carrot, lettuce, tomato, potato, maize,
soya bean, rice and banana (Ahmad et al., 2012; Azegami et al., 2014).

Author Manuscript

Oral vaccines can effectively elicit humoral and cellular immunity of both the mucosal and
systemic immune systems and eliminate undesired pain and discomfort from injections and
needle-associated risks (Kwon et al., 2013b). Plant-derived antigens can induce antigenspecific mucosal IgA and serum IgG synthesis when delivered orally to mice and humans
(Sack et al., 2015). Plant-based antigens can be fed directly to animals or humans without
purification or processing. Transgenic plants are ideal for producing oral vaccines because
the antigenic proteins are protected from the acidic environment in the stomach by the plant
cell wall, enabling antigens to reach the gut-associated lymphoid tissue (GALT) (Limaye et
al., 2006; Ruhlman et al., 2007; Verma et al., 2010). Several recent studies have
Plant Biotechnol J. Author manuscript; available in PMC 2016 February 28.
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unequivocally shown that bioencapsulation of antigens within the plant cell wall protects
them from the acids and enzymes in the stomach (Boyhan and Daniell, 2011; Kwon et al.,
2013a; Shenoy et al., 2014; Shil et al., 2014). Although human digestive enzymes do not
hydrolyse glycosidic bonds of plant cell wall carbohydrates, commensal microbes are able to
digest and release protein drugs into the gut lumen. Bacteria inhabiting the human gut have
evolved to hydrolyse almost all plant glycans (Martens et al., 2011). Bacteria colonizing the
large intestine are greater in number and digest plant cells that escape the upper gut (Flint et
al., 2008). Orally delivered insulin or exendin bioencapsulated in plant cells lowers blood
sugar levels within 30 min (Boyhan and Daniell, 2011; Kwon et al., 2013a). Histological
studies provide ample evidence for the delivery of protein drugs across the gut epithelium
throughout the ileum in the villi and Peyer’s patches (Sherman et al., 2014; Verma et al.,
2010; Wang et al., 2015). Therefore, there is new evidence for the role of microbes in the
small intestine in the release of protein drugs from plant cells in the gut lumen.
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The cholera toxin B subunit (CTB) from Vibrio cholerae and the heat-labile (LT)
enterotoxin B subunit (LTB) of Escherichia coli are well-characterized bacterial proteins
that have strong potential as mucosal carrier proteins (Chia et al., 2011; Lakshmi et al.,
2013). Recombinant CTB was approved for human use a decade ago and is used by
hundreds of millions of people worldwide (Hill et al., 2006). When expressed in plants,
CTB assembles into pentamers and acts as an effective carrier of fused foreign proteins to
elicit immune responses in mice (Daniell et al., 2001; Davoodi-Semiromi et al., 2010). CTB
and LTB are mucosal immunogens and induce both mucosal and systemic responses after
administration through the mucosal surface or systemic delivery. The biological functions of
CTB and LTB are dependent on their forming pentamers, which then bind to GM1ganglioside receptors on the surface of the intestinal epithelial cells (Daniell et al., 2001).
Hence, both pentameric CTB and LTB function as carrier proteins for genetically fused
antigens, and they can deliver these antigens across the mucosal epithelium to the
underlying mucosa-associated lymphoid tissue (MALT) (Chia et al., 2011; Czerkinsky and
Holmgren, 2010; Davoodi-Semiromi et al., 2010). CTB-fused autoantigens are ideal for the
induction of oral tolerance, when delivered without priming (Ruhlman et al., 2007; Sherman
et al., 2014; Verma et al., 2010; Wang et al., 2015).

Mechanism of the mucosal immune response
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The mucosal immune system in the gut is regulated by mechanisms that initiate protective
immune responses against pathogens while preventing responses to harmless intestinal
antigens from food or commensals (Wang et al., 2013). Lymphocytes in the mucosa are
organized into structures known as MALT, which can be subdivided into the sites in which
they are found, such as the bronchus-associated lymphoid tissue and the GALT (Czerkinsky
and Holmgren, 2010). The GALT is the largest human mucosa and immunologic organ in
the body. Within the intestinal GALT, Peyer’s patches are the most recognized lymphoid
organs, and they can be observed as lymphoid aggregates clustered in the ileum of the small
intestine (Figure 1; Thanavala and Lugade, 2010). Microfold (M) cells residing in the
follicle-associated epithelium (FAE) overlying the Peyer’s patches are specialized epithelial
cells that take up antigens or microorganisms from the intestinal lumen by endo-, phago-, or
pinocytosis and transcytosis and transport them to the underlying immune system of the
Plant Biotechnol J. Author manuscript; available in PMC 2016 February 28.

Chan and Daniell

Page 4

Author Manuscript
Author Manuscript

mucosae (Azizi et al., 2010). Most studies have identified both the mesenteric lymph nodes
and the Peyer’s patches as the major sites for antigen presentation and T-cell activation in
response to orally delivered antigens in mouse models (Thanavala and Lugade, 2010).
Antigen uptake could also occur by other mechanisms, for instance via the intestinal
dendritic cells (DCs). It has been proposed that antigens taken up by M cells and transported
into the Peyer’s patches induce intestinal IgA antibodies, whereas those taken up by the DC
induce systemic IgG antibodies (Hernández et al., 2014). The immune response to intestinal
antigens primarily produces IgA from B cells and generates T cells that secrete the Th2associated cytokines interleukin 4 [IL-4, a cytokine involved in the differentiation of naive
helper T cells (Th0 cells) to Th2 cells], interleukin 10 [IL-10, an anti-inflammatory cytokine
also known as human cytokine synthesis inhibitory factor (CSIF)] and transforming growth
factor-β (TGF-β, an immune suppressive cytokine involved in the induction of tolerance)
rather than the Th1-associated interferon-γ (IFN-γ, a cytokine involved in the regulation of
immune and inflammatory responses) (Lamichhane et al., 2014). The ability of M cells in
the Peyer’s patches to take up and transcytose diverse numbers of microorganisms and
antigens to antigen-presenting cells (APCs) has made M cells a prime target to enhance oral
vaccine efficacy (Azizi et al., 2010; Yuki and Kiyono, 2009).
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Antigen uptake by the GALT is inefficient partly because of the proteolytic and acidic
stomach environment. Bioencapsulated antigens fused with CTB are protected from stomach
acids and enzymes but are released into the immune system in the gut (Davoodi-Semiromi et
al., 2010; Limaye et al., 2006). Orally administered antigens form the pentameric structure
required for binding to GM1 gangliosides on the intestinal epithelial cells, thereby allowing
for endocytosis (Limaye et al., 2006). Antigen–CTB-GM1 complexes then traffic through
the trans-Golgi network (TGN) and into the lumen of the endoplasmic reticulum (ER),
releasing the fused antigen via proteolytic cleavage of the furin cleavage site between CTB
and the antigen in the TGN. Then, the antigen is exocytosed and released into the
extracellular fluid, whereas CTB is retained intracellularly (Verma et al., 2010). Antigens
are primarily sampled and processed in the intestine by mononuclear phagocytes, including
macrophages and DCs, which are critical for the differentiation, expansion and maintenance
of Tregs (regulatory T cells expressing immune suppressive cytokines). Systemically
delivered protein antigens in the gut have been found to be taken up by F4/80+ and CD11c+
cells in the ileum (Wang et al., 2015).

Evidence for oral delivery with bioencapsulated vaccine antigens in mice
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To understand the oral delivery route of plant-based recombinant proteins that circulate in
the body after administration, mice were fed leaves expressing CTB fused with greenfluorescent protein (CTB–GFP) with a furin cleavage site between CTB and GFP. GFP
fluorescence was observed in the intestinal mucosa, liver and spleen, indicating that CTB–
GFP had been taken up by the enterocytes and the GALT through GM1 receptor binding of
pentameric CTB–GFP (Limaye et al., 2006). Haemophilia A and B patients are deficient in
producing blood clotting factors VIII (FVIII) and IX (FIX), respectively, and their treatment
involves intravenous infusion of these factors. However, some patients develop antibodies
that are toxic and cause anaphylaxis. Therefore, FIX fused with CTB expressed in
chloroplasts and bioencapsulated in plant cells has been orally delivered to induce tolerance.
Plant Biotechnol J. Author manuscript; available in PMC 2016 February 28.
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The furin cleavage site is commonly used because furin is ubiquitous protease and is present
in all cell types (Kwon et al., 2013a). Oral delivery of protein drugs fused with furin was
efficiently cleaved, releasing functional protein into the circulatory system (Kohli et al.,
2014; Kwon et al., 2013a; Shenoy et al., 2014; Shil et al., 2014; Verma et al., 2010).
Consistent with previous findings, CTB was translocated across the epithelial cell barrier
and did not co-localize with FIX due to efficient furin cleavage between FIX and CTB
(Verma et al., 2010; Wang et al., 2015). Stains of the spleen showed positive labelling for
FIX but not CTB, which was expected because CTB is retained within the cell, while
cleaved FIX is in part systemically delivered (Verma et al., 2010). Most importantly, the
furin cleavage site (NH2-R-R-K-R-COOH) is cut without leaving any extra amino acid on
the fused protein.
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Immunohistochemical analysis of tissue from mice fed with CTB-FFIX (with furin cleavage
site)-expressing plant cells twice per day for 2 days showed that the FIX antigen was
delivered to the epithelial M cells and the CD11c+ dendritic cells in the Peyer’s patches that
form the interface between the GALT and the luminal microenvironment. Moreover, the
FIX antigen was also observed in the plasma and liver within 2–5 h of feeding,
demonstrating systemic delivery of the FIX antigen into circulation (Kwon et al., 2013b;
Verma et al., 2010). FVIII antigen that was orally delivered to the GALT was shown by
immunostaining to be in the epithelial cells and delivered to the dendritic cells in the lamina
propria and Peyer’s patches of the small intestine. The furin cleavage site between the CTB
and FVIII sequences facilitated the systemic delivery of the FVIII antigen after uptake in the
gut. Further, heavy-chain (HC) antigen was observed in plasma samples and liver protein
extracts from mice with haemophilia A 5 h after the last gavage (Sherman et al., 2014).
There are examples in which CTB fusion proteins induced tolerance (Ruhlman et al., 2007;
Sherman et al., 2014; Verma et al., 2010; Wang et al., 2015). Unfortunately, CTB-fused
vaccine antigens have not yet been investigated using histopathological studies. CTB-fused
vaccine antigens stimulated antigen-specific IgG and IgA after priming and oral boosters,
conferred protection against toxin/pathogen challenge, increased IL-10 but not FoxP3+
regulatory T cells [regulatory T cells expressing the transcription factor forkhead box P3
(FoxP3), which is involved in immunological self-tolerance], suppressed IFN-γ,
interleukin-17 (IL-17, a cytokine involved in proinflammatory responses) and conferred
immunity via the Th2 immune response (Davoodi-Semiromi et al., 2010).

Stable transformation platforms used for plantderived vaccine production
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Plants are proving to be attractive bioreactors to produce biopharmaceutical proteins,
including vaccines, antibodies and immunomodulatory molecules such as cytokines. The
main challenges for plant-derived recombinant antigens include low yields, the long process
required to generate transgenic plant lines, and the associated scale-up costs (Hernández et
al., 2014). Thus, different strategies to improve protein yield have been investigated
recently. Table 1 summarizes recent examples of plant-derived oral vaccines against human
infectious diseases.

Plant Biotechnol J. Author manuscript; available in PMC 2016 February 28.
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Stable nuclear transformation involves transgene integration into the plant nuclear genome,
leading to the expression of therapeutic proteins and Mendelian inheritance of the
introduced trait (Figure 2). Stable integration into the nuclear genome allows for continual
production of recombinant proteins, simultaneously reducing costs and simplifying
production (Tremblay et al., 2010). Nuclear-expressed recombinant proteins undergo typical
eukaryotic post-translational modifications and can be stored in subcellular organelles or
secreted, depending on the fused signalling peptides (Egelkrout et al., 2012; Tremblay et al.,
2010). However, the potential for outcrossing with native species or food crops and the long
production cycle of certain crops limit public acceptance of this method (Obembe et al.,
2011). The relatively low-level accumulation of recombinant proteins is a major limitation
for generating a protective immune response. Modulation of gene expression in plants to
enhance accumulation of target proteins could be achieved by using efficient promoters,
adding specific signal sequences and optimizing several molecular factors like GC content,
codon bias, incorporation of 5′ and 3′ regulatory sequences and elimination of cryptic
splicing sites, putative polyadenylation signals, and mRNA-destabilizing sequences
(Egelkrout et al., 2012; Peters and Stoger, 2011).
The first plant-based oral vaccine, which used tobacco and potato to produce recombinant
LTB from E. coli, induced low levels of both serum IgG and secretory IgA (sIgA) antibodies
in mice after oral administration (Haq et al., 1995). Various plants have been used to
develop edible plant vaccines, including leafy crops, cereals, legumes, fruits and vegetables
(Ahmad et al., 2012). Although the first nuclear genome engineering was accomplished in
1995, two decades of research and development have not yet resulted in a single approved
vaccine worldwide.
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Chloroplast transformation system
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Chloroplast transformation has been developed into a highly efficient expression system for
recombinant protein production. In the chloroplast technology, site-specific integration of
foreign genes into the chloroplast genome occurs by homologous recombination, eliminating
the variation in expression caused by gene silencing, positional effects and pleiotropic
effects among independent transgenic lines (Daniell et al., 2009; Ruhlman et al., 2010).
Moreover, the prokaryotic nature of the chloroplast makes multigene engineering via
chloroplast transformation possible (De Cosa et al., 2001; Kumar et al., 2012). Foreign gene
products regulated by the endogenous psbA promoter and 5′-untranslated region (UTR) and
the psbA 3′-UTR express up to 72% of the total soluble protein (TSP) of transplastomic
plants (Ruhlman et al., 2010). The species specificity of the regulatory sequences
dramatically affects transgene expression levels (Ruhlman et al., 2010). Use of the
transcriptionally active spacer region between the trnI and trnA genes within the ribosomal
operon and two copies of the transgene, which integrates into the inverted repeat regions of
the chloroplast genome, resulted in the highest levels of transgene expression (Clarke and
Daniell, 2011; Ruhlman et al., 2010).
Field trials have been conducted a decade ago using transplastomic plants expressing
biopharmaceuticals or vaccine antigens (Arlen et al., 2007). Chloroplast genomes are

Plant Biotechnol J. Author manuscript; available in PMC 2016 February 28.
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maternally inherited, offering transgene containment via pollen (Daniell, 2002, 2007).
Antigen expression in leaves offers the opportunity to harvest them prior to the appearance
of any reproductive structures, facilitating complete transgene containment via both pollen
and seeds. Most importantly, a USDA-APHIS certification (dated 1/30/2013 to Dr. Daniell)
stated that transplastomic lines do not fit the definition of a regulated article under USDAAPHIS regulations 7 CFR part 340 because there are no plant pest components. Therefore,
>300 transplastomic lines expressing transgenes from different kingdoms were moved
across state lines (from Florida to Pennsylvania) based on this USDA-APHIS certification.
These recent developments should facilitate the commercial development of transplastomic
lines expressing vaccines or biopharmaceuticals. However, the major limitation of
recombinant proteins expressed in tobacco is that they are not suitable for oral delivery.
Thus, optimized expression of antigen proteins in the chloroplasts of edible crops is
necessary (Davoodi-Semiromi et al., 2010; Ruhlman et al., 2010).
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Although chloroplast transformation protocols have been developed for a few edible crops
like potato, carrot and tomato, the expression level of the foreign gene in the edible parts of
these plants is not adequate for using such systems to produce vaccines or
biopharmaceuticals. Compared with chloroplasts in photosynthetically active tissues, nongreen plastids like chromoplasts generally have much lower gene expression activity due to
the suppression of plastid gene expression through the interplay between transcriptional and
translational control in non-green tissues (Caroca et al., 2013). Therefore, edible leafy
vegetables are ideal for biopharmaceutical applications. The lettuce chloroplast system has
been successfully used to express a number of vaccines and biopharmaceuticals (Boyhan
and Daniell, 2011; Davoodi-Semiromi et al., 2010; Kanagaraj et al., 2011; Maldaner et al.,
2013). Chloroplasts permit high gene expression levels and facilitate several posttranslational modifications that are required for bioactivity such as pentamer assembly,
disulphide bond formation, cyclization, protein lipidation and N-terminal methionine
excision, but glycosylation does not occur in chloroplasts (Boyhan and Daniell, 2011;
Davoodi-Semiromi et al., 2010; Kohli et al., 2014; Kwon et al., 2013a; Scotti et al., 2012;
Sherman et al., 2014; Shil et al., 2014; Verma et al., 2010). The expression of a thioredoxin
in chloroplasts enhanced protein solubility, proper folding and disulphide bond formation
(Sanz-Barrio et al., 2011). The human papillomavirus (HPV) L1 protein was shown to selfassemble into virus-like particles (VLPs) within chloroplasts (Fernández-San Millán et al.,
2008; Waheed et al., 2011a). Structures resembling VLPs were observed as aggregates of
subviral particles in chloroplast extracts from transplastomic lettuce producing the dengue
prM/E protein, suggesting that the prM/E proteins folded properly and were able to
assemble into higher order structures (Kanagaraj et al., 2011). Chloroplast-derived HPVL1
protein self-assembles into capsomeres, which play an important role in the induction of
neutralizing antibodies and T-cell responses (Waheed et al., 2011b). The L1 protein was
also expressed, and it self-assembled into VLPs in tobacco chloroplasts, suggesting no
processing requirement via ER for VLP formation in chloroplasts. Further, the HPV L1
protein showed high immunogenicity and neutralizing antibody production in mice
(Fernández-San Millán et al., 2008; Kanagaraj et al., 2011).
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Illustrative examples of plant-based vaccines against human infectious
diseases
Respiratory infections
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Influenza is a serious respiratory disease caused by influenza viruses. It has caused global
pandemics, and its prevention is one of the world’s greatest public health challenges because
of mutations that cause antigenic variation in haemagglutinin (HA) (Shoji et al., 2011). HA
is a surface glycoprotein of the influenza virus and plays a key role in viral infectivity and
pathogenesis. HA is also the main target for generating protective immunity against the
influenza virus (Phan et al., 2013). Recent outbreaks caused by the new H1N1 swine
influenza virus infected a large number of humans and raised significant concerns as a
global pandemic. The virus, A(H1N1) pdm09, is a triple reassortant with genes acquired
from swine, avian and human influenza viruses and was first detected in humans in the
United States in April 2009 (Cummings et al., 2014). The highly pathogenic avian influenza
A virus (H5N1) caused pandemics in poultry and carries a risk of global human infection
due to wide circulation and rapid evolution of the virus (Lee et al., 2015). The antigenicity
of the HA protein depends on its proper folding and trimerization, and it also requires
multiple post-translational modifications including disulphide bond formation and
glycosylation (de Vries et al., 2012). The expression of HA without its transmembrane
domain from the A/Hong Kong/213/03 (H5N1) influenza virus strain fused with an ERtargeting signal at the 5′ end and the HDEL ER retention motif at the C-terminus resulted in
its high-level accumulation in the ER (140 μg/g fresh weight, FW), N-glycosylation,
protection from proteolytic degradation and long-term stability in Arabidopsis. Oral
administration of freeze-dried leaf powder expressing this HA antigen and the adjuvant
saponin together elicited not only high levels of HA-specific mucosal IgA and systemic IgG
responses in mice, but also neutralizing antibodies and cellular immune responses,
conferring protection against a lethal viral challenge. Although the trans-membrane domain
is essential for the trimerization that is required for HA antigenicity, plant-based HA without
the transmembrane domain still can induce strong HA-specific immune responses in mice
(Lee et al., 2015). The influenza virus nucleoprotein (NP) is a highly conserved
multifunctional RNA-binding protein found in many different strains, making it a potential
candidate for a universal vaccine. Oral immunization of maize-expressed H3N2 NP induced
humoral immune responses in mice, showing the immunogenicity of this maize-based
antigen and its potential as a universal flu vaccine candidate. The NP protein level in T1
transgenic maize seeds ranged from 8.0 to 35 μg/g of corn seed, and this level increased to
up to 70 μg NP/g in T3 seeds. Cytokine analysis showed antigen-specific stimulation of IL-4
cytokines in splenocytes from mice orally administered with NP, further confirming a Th2
humoral immune response (Nahampun et al., 2015).
Tuberculosis (TB), caused by Mycobacterium tuberculosis (MTB), is a leading bacterial
infectious disease that is re-emerging due to drug-resistant strains worldwide (Lakshmi et
al., 2013). In 2013, there were 9.0 million cases of TB, with an estimated 480 000
multidrug-resistant TB cases and 1.1 million HIV-positive individuals. More than half
(56%) of these cases appeared in South East Asia and the Western Pacific. Further,
approximately 25% were in Africa, which suffered the highest rates of cases and deaths
Plant Biotechnol J. Author manuscript; available in PMC 2016 February 28.
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relative to the population. China and India accounted for 11% and 24% of total cases,
respectively (WHO, 2014a). The 6 kDa early secretory antigenic target (ESAT6) and culture
filtrate protein 10 (CFP10) proteins are among the key cell virulence factors of MTB and
have been expressed in transgenic carrot plants, where ESAT6 makes up <0.056% and
CFP10 composes 0.002% of the total storage protein in carrot storage roots. Oral
immunization of mice induced both cell-mediated and humoral immune responses (Uvarova
et al., 2013). Fusion of the ESAT6 antigen with other tuberculosis antigens, such as Ag85B
or Mtb72F (a fusion polyprotein of two TB antigens, Mtb32 and Mtb39), and use of a
transmucosal carrier such as CTB, LTB and LipY (a cell wall protein) to facilitate
bioencapsulation/oral delivery, and further expression in various plant species (Arabidopsis
thaliana, tobacco and lettuce), have been attempted (Floss et al., 2010; Lakshmi et al., 2013;
Uvarova et al., 2013). Compared with nuclear transgenic plants, the expression levels of
CTB-ESAT6 and CTB-Mtb72F in transplastomic plants reached up to 7.5% and 1.2% of
TSP, respectively, increasing antigen accumulation >100 fold (Lakshmi et al., 2013). CTBESAT6 was expressed up to 0.75% of the total leaf protein in transplastomic plants. Western
blot analysis of lyophilized lettuce leaves stored for up to 6 months at room temperature
revealed the stability of the CTB-ESAT6 fusion protein, which retained proper folding,
disulphide bond formation and assembly into pentamers for prolonged periods. ESAT6 is
one of the secreted proteins in the ESX-1 system, which is involved in membrane pore
formation during infection. A haemolysis assay indicated the ability of chloroplast-derived
ESAT6 to lyse red blood cell membranes in a dose-dependent manner (Lakshmi et al.,
2013).
Gastroenteritis and hepatitis
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Diarrhoeal infectious diseases (DID) are a major problem in developing countries, where
poor sanitation prevails and food and water may become contaminated by faecal shedding
(Böhles et al., 2014). Traveller’s diarrhoea and cholera, caused by enterotoxigenic strains of
Eschericia coli (ETEC) and Vibrio cholerae, respectively, are two enteric diseases resulting
in high mortality, especially in young children in developing countries (Karaman et al.,
2012). CTB was expressed in maize seeds driven by a γ-zein promoter and accumulated in
the endosperm of transgenic maize kernels with an expression level of 0.0014% of the total
aqueous soluble protein (TASP) in the T1 generation and significantly increased to 0.0197%
of TASP in the T2 generation. Anti-CTB IgG and IgA were detected in the sera and in
faecal samples from orally administered mice, and the mice were protected against CT
holotoxin challenge (Karaman et al., 2012). Inclusion of a heat-stable (ST) toxin into
vaccine formulations is required, as most ETEC strains can produce both LT and ST
enterotoxins. Transgenic tobacco plants carrying the LTB:ST gene accumulated up to 0.05%
of TSP, and oral dosing with transgenic tobacco leaves elicited specific mucosal and
systemic humoral responses in mice, although the authors did not provide antibody titres or
any quantitative measurement of the response (Rosales-Mendoza et al., 2011). In
comparison, lettuce chloroplast-derived CTB-AMA1 and CTB-MSP1 expressed up to 7.3%
and 6.1% of TSP, which is >100-fold higher expression than from the nuclear genome.
CTB–proinsulin expressed up to 70% of TSP, suggesting that the fusion protein, not CTB,
determines the expression level. CTB-specific antibody titres were incredibly high (up to 10
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000 IgA, >800 000 IgG1) and also conferred protection against CT challenge in mice,
providing long-term immunity (Davoodi-Semiromi et al., 2010).
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Hepatitis B virus attacks the liver and results in both acute and chronic disease, and it
remains a major global health problem despite the availability of a safe and effective
vaccine. Each year, hepatitis B infection causes approximately 780 000 deaths, 130 000
from acute hepatitis B and another 650 000 from liver cancer and cirrhosis due to chronic
hepatitis B infection (Lozano et al., 2012). The expression level of the major surface antigen
of hepatitis B virus (P-HBsAg) reached 0.003–0.09% of TSP in transgenic potato. Mice
produced specific faecal IgA and serum IgG antibodies against P-HBsAg after oral
administration (Youm et al., 2010). Herbicide-resistant lettuce was engineered to stably
express the small surface antigen of hepatitis B virus (S-HBsAg) (Pniewski et al., 2011).
The progeny of these plants accumulated up to micrograms of antigen per gram of FW, and
the S-HBsAG antigen was able to form VLPs (Pniewski et al., 2011). Oral delivery of
lyophilized lettuce containing low levels (100 ng) of VLP-assembled antigen with a long, 2month interval between priming and boost administrations without adjuvant elicited both
mucosal and systemic humoral anti-HB responses at the nominally protective level in mice.
Lyophilized material, both as a powdered, semi-finished product or after conversion into
tablets, preserved the S-HBsAg content for at least 1 year of room-temperature storage
(Pniewski et al., 2011). Bioencapsulated HBsAg expressed in maize reached between 0.08
and 0.46% of TSP and induced serum IgG and IgA in mice after oral administration
(Hayden et al., 2012b). High levels of HBsAg were obtained in maize grains, and
supercritical fluid extraction (SFE)-treated maize material was used to form edible wafers.
After feeding wafers containing approximately 300 μg/g HBsAg, mice showed robust serum
IgG (20 000 mIU/mL) and IgA responses. Additionally, all mice administered the SFE
wafers showed high sIgA and salivary IgA titres (142 mIU/mL) in faecal material, whereas
Recombivax® Merck & Co., Inc., Whitehouse Station, NJ, USA (an injected commercial
vaccine)-treated mice showed no detectable titre (Hayden et al., 2014). Furthermore, mice
boosted with orally administered HBsAg wafers displayed long-term memory mucosally
and systemically, as evidenced by sustained faecal IgA and serum IgA, IgG and mIU/mL
over 1 year (Hayden et al., 2015). Freeze-drying of S-HBsAg expressed in lettuce leaf tissue
without any purification step was shown to be an important factor affecting S-HBsAg
preservation. This reproducible process provided a product with VLP content up to 200 μg/g
dry weight. Long-term stability tests showed that the stored freeze-dried product was stable
at 4 °C for 1 year but degraded at room temperature. Animal oral immunization trials
induced systemic IgG in mice (293 mIU/mL), confirming the preservation of antigenicity
and immunogenicity (Czyż et al., 2014).
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Human immunodeficiency virus
Human immunodeficiency virus (HIV), which causes acquired immune deficiency
syndrome (AIDS), is one of the most severe infectious diseases worldwide. AIDS evolved as
an alarming public health problem with very high costs for government agencies in most
developing and African countries (Rosales-Mendoza et al., 2012). The HIV-1 capsid protein
p24 antigen expressed in both transgenic Arabidopsis and carrot showed a priming effect in
mice and induced specific anti-p24 IgG in sera after an intramuscular p24 protein boost.
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Further, dose-dependent antigen analyses using transgenic A. thaliana revealed that low p24
antigen doses were superior to high doses, indicating the induction of tolerance (Lindh et al.,
2014). The accumulation of HIV-1 p24 and a fusion of p24 with the negative regulatory
protein Nef (p24-Nef) reached 4% and 40% of TSP, respectively, in the leaves of
transplastomic tobacco plants. Subcutaneous immunization with purified chloroplast-derived
p24 induced a strong antigen-specific serum IgG response, with titres of up to 1 : 6400 for
IgG1 and 1 : 3200 for IgG2a. Oral delivery of partially purified chloroplast-based p24-Nef
fusion protein as a booster after subcutaneous injection with either Nef or p24 elicited strong
antigen-specific serum IgG responses (in IgG titres of 3200–12 800). Additionally, after
subcutaneous and oral immunization, both IgG1 and IgG2a subtypes, which correlate with
cell-mediated Th1 and humoral Th2 responses, respectively, were detected in sera
(Gonzalez-Rabade et al., 2011). The synthetic C4V3 peptide, which includes the C4 domain
and the V3 loop from HIV gp120, was introduced into tobacco chloroplasts and expressed at
up to 25 μg/g FW in the leaves. Plant-derived C4V3 elicited both mucosal and systemic
immune responses, but the antibody titres were not quantified; CD4+ T-cell proliferation
responses were observed (Rubio-Infante et al., 2012). A lettuce-based C4(V3)6 multiepitopic protein within the V3 loops, corresponding to five different HIV isolates including
CC, MN, IIIB, RF and RU, elicited local and systemic immune responses when orally
delivered to BALB/c mice. In addition, the induction of significant T-helper responses by
the C4(V3)6 immunogen was shown in splenocyte proliferation assays (Govea-Alonso et
al., 2013). Multi-HIV, a multi-epitopic protein consisting of the C4, V1, V2, V3 domains
and the ELDKWA epitope derived from the gp120 and gp41 envelope proteins of HIV,
respectively, was expressed in tobacco chloroplasts. Mice orally immunized with the
tobacco-derived Multi-HIV antigen indicated an immune response, but antibody titres were
not provided. Furthermore, specific IFN-γ production was observed in both CD4+ and CD8+
T cells stimulated with HIV peptides, demonstrating that plant-derived Multi-HIV induces T
helper-specific responses (Rubio-Infante et al., 2015).
Human papillomaviruses
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Cervical cancer caused by HPV infection is the fourth most common cancer among women
worldwide and has become a global concern, particularly in developing countries, which
bear approximately 80% of the burden (Ferlay et al., 2015). Furthermore, HPV type 16 is by
far the most prevalent type and is correlated with 54% of cervical cancer cases (Waheed et
al., 2012). Higher levels of specific IgG and IgA levels (<1 : 1000 for the L1/LT-B group
and <1 : 500 for the L1 group) of HPV-16L1 (major capsid protein) were induced when
mice were immunized with transgenic tobacco-derived HPV-16L1 combined with LTB by
the oral route (Liu et al., 2013). A novel HPV 16L1-based chimeric virus-like particle
(cVLP) expressed in tomato plants contains a string of T-cell epitopes from HPV-16 E6 and
E7 fusion at the C-terminus. Long-lasting specific IgG antibodies with neutralizing activity
were detectable for 12 months after induction by immunization with cVLPs. Efficient longterm protection and tumour growth inhibition were elicited by TC-1 tumour cells expressing
HPV-16 E6/E7 oncoproteins, whereas significant tumour reduction (57%) was observed in
mice administered with these cVLPs (Monroy-García et al., 2014).
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Rabies virus is an enveloped, negative-sense, single-stranded RNA virus of the genus
Lyssavirus in the family Rhabdoviridae. This zoonotic disease causes acute, progressive,
incurable viral encephalomyelitis and is usually transmitted through the bite of an infected
animal, resulting in 40 000–100 000 human deaths annually worldwide (Hermann et al.,
2011). The expression level of the rabies virus glycoprotein protein (G protein) in transgenic
maize kernels reached 25 μg/g FW. Neutralizing antibodies in sheep were induced after oral
immunization with maize-derived G protein. Further, the degree of protection achieved with
2 mg of maize-based G protein was comparable to that of a commercial vaccine (LozaRubio et al., 2012). Transgenic hairy roots of Solanum lycopersicum were engineered to
express the rabies glycoprotein fused with ricin toxin B chain (rgp-rtxB) antigen driven by a
constitutive CaMV35S promoter. The expression level of the RGP-RTB fusion protein in
different tomato hairy root lines ranged from 1.4 to 8 μg/g of tissue. A partially purified
RGP-RTB fusion protein was able to induce an immune response in BALB/c mice after
intramucosal immunization, but the IgG titres were low (Singh et al., 2015).
Malaria
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Malaria is a mosquito-borne infectious disease caused by Plasmodium parasites (Jones et al.,
2013). According to the World, Malaria Report (2014), approximately 198 million clinical
cases of malaria were reported worldwide in 2013, predominantly in developing countries in
South East Asia and sub-Saharan Africa. Approximately 82% of malaria cases and 90% of
malaria deaths occurred in the WHO African Region, mostly among children under the age
of 5 years (WHO, 2014b). Plasmodium falciparumis is responsible for the majority of the
over half a million malaria deaths per year, which are predominantly children under the age
of five that live in indigent African nations (Gregory and Mayfield, 2014). A chloroplastderived dual cholera and malaria vaccine expressing CTB fused with the malarial vaccine
antigens apical membrane antigen 1 (AMA1) and merozoite surface protein 1 (MSP1)
accumulated up to 13.17% and 10.11% of TSP in tobacco and up to 7.3% and 6.1% of TSP
in lettuce, respectively. The AMA and MSP titres were lower than those of CTB, suggesting
that the CTB antigen could saturate the immune system. Significant levels of antigenspecific antibody titres in orally immunized mice not only cross-reacted with the native
parasite proteins in immunofluorescence studies and immunoblots, but also completely
inhibited the proliferation of the malarial parasite (Davoodi-Semiromi et al., 2010). Oral
immunization of mice with the MSP1 and circumsporozoite protein (CSP) fusion protein
(MLC) chimeric recombinant protein expressed in B. napus successfully elicited antigenspecific IgG1 production. Additionally, the Th1-related cytokines interleukin 12 (IL-12, a
cytokine involved in the differentiation of naive T cells into Th1 cells), TNF (tumour
necrosis factor, a cytokine involved in the inflammatory process and apoptosis) and IFN-γ
were significantly increased in the spleens of immunized mice (Lee et al., 2011).
Toxoplasma gondii—Infection by the intracellular parasitic protozoan Toxoplasma
gondii can cause complications in pregnant women and in immunodeficient individuals such
as patients with AIDS and organ transplant recipients (Guo et al., 2015). Recent studies have
shown the possible roles of chronic toxoplasmosis infection in the aetiology of certain
mental disorders, such as schizophrenia (Parlog et al., 2015). Expression of the T. gondii
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dense granular protein 4 (GRA4) antigen via chloroplast transformation (chlGRA4) led to its
accumulation to approximately 6 μg/g FW (0.2% of total protein) in tobacco plants. Oral
immunization with chlGRA4 elicited both mucosal and systemic immunity (<1000 IgG
titre) and also showed a 59% decrease in the brain cyst load of mice. Chloroplast-derived
GRA4 induced a protective immune response against Toxoplasma infection by reducing
parasite loads in mice, correlating with a mucosal and systemic balanced Th1/Th2 response
(Del L. Yácono et al., 2012). Toxoplasma gondii main surface antigen (SAG1) fused with
the 90-kDa heat-shock protein from Leishmania infantum (LiHsp83) as a carrier was
expressed in transplastomic tobacco plants. SAG1 protein expression levels reached up to
0.1–0.2 μg/g FW in tobacco and reacted with human seropositive samples in a functional
analysis. Oral immunization with chLiHsp83-SAG1 induced a significant reduction in the
cyst burden in mice, which correlated with an increase in specific anti-SAG1 antibodies
(Albarracín et al., 2015).

Author Manuscript
Author Manuscript

Taenia solium—Taenia solium cysticercosis is an endemic parasitic disease that affects
human health and the economy in developing countries. Cysticercosis cysts in the central
nervous system produce neurocysticercosis (NCC) and are a common cause of acquired
epilepsy (Garcia et al., 2014). The S3Pvac vaccine components (KETc1, KETc12, KETc7
and GK1 [KETc7]) and the protective HP6/TSOL18 antigen were expressed using a
Helios2A polyprotein system through the ‘ribosomal skip’ mechanism. The 2A sequence
(LLNFDLLKLAGDVESNPG-P) derived from the foot-and-mouth disease virus induces
self-cleavage events at the translational level, releasing the distinct antigens in a single
transformation and expression event. Plant-derived Helios2A accumulated up to 1.3 μg/g
FW in transgenic tobacco leaf tissue and was recognized by antibodies in the cerebrospinal
fluid from patients with NCC in a functional assay. Further, orally immunized mice elicited
an immune response, but antibody titres were not reported (Monreal-Escalante et al., 2015).

Future perspectives
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The plant-made vaccine field started two decades ago with the promise of developing lowcost vaccines to prevent infectious disease outbreaks and epidemics around the globe, but
this goal has not yet been realized. A few clinical trials have been conducted a decade ago
using lettuce leaves (Kapusta et al., 1999), maize seeds (Tacket et al., 2004) and potato
tubers (Tacket et al., 1998, 2000; Thanavala et al., 2005) expressing different vaccines
antigens. However, none of them advanced beyond phase I clinical trial or result in any
licensed product. There are a number of major technical hurdles to achieve this goal,
including inadequate expression levels in edible plant systems and the low success of oral
priming to induce adequate immunity against pathogens (Egelkrout et al., 2012; Pasetti et
al., 2011; Wahid et al., 2011). The major advantage of the oral vaccination system is the
stimulation of both mucosal and systemic immunity (Davoodi-Semiromi et al., 2010).
Compared with conventional vaccination by injection into the bloodstream with adjuvants,
the mucosal immune system requires much higher antigen doses because the antigens do not
cross the epithelial barrier and reach the immune system, but rather are degraded by acids
and enzymes in the digestive system (Davitt and Lavelle, 2015). Although the latter concern
is addressed by the bioencapsulation of vaccine antigens within plant cells, transmucosal
carriers must be fused with the antigens for the delivery across epithelial barriers (with rare
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exceptions in which an antigen such as CTB may have the ability to directly bind the GM1
receptor present in human gut epithelial cells). Foreign proteins without transmucosal
carriers are not delivered to the immune system or into circulation (Kohli et al., 2014;
Limaye et al., 2006). Very few vaccine candidates described above meet these requirements,
and therefore, their efficacy has not been tested in suitable animal models or they were not
effective enough to warrant further advancement to the clinic. Candidates that meet these
criteria in successful studies and demonstrated the efficacy of oral vaccines in boosting the
immune system and conferring greater/prolonged protection against pathogen challenge
were not successful for priming. The requirement of priming by injection faces the same
challenges of prohibitively expensive protein purification, cold storage/transportation and
short shelf life or stability (Kwon et al., 2013b). Therefore, the key advantages of low-cost
and cold-chain-free plant-made vaccines have not yet been achieved using such technology.
Furthermore, only a few vaccine antigens have been expressed in edible crops (lettuce), and
those expressed in tobacco would face challenges in the FDA approval process because of
concerns about nicotine in orally delivered drugs.
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Plant-derived vaccine antigens can accumulate in and are protected by compartments such
as plastids or seed storage organelles such as ER-derived protein bodies (PBs), as well as de
novo formed protein storage vacuoles (PSVs). This bioencapsulation shields the antigens
from chemical, thermal and enzymatic degradation (Kwon et al., 2013b; Sack et al., 2015).
Freeze-dried leaf material expressing vaccine antigens can often be stored at ambient
temperatures while maintaining antigen integrity (Kwon et al., 2013b). Plant cells can be
lyophilized and stored at room temperature without antigen degradation for several months
or years (Kwon et al., 2013a). Lyophilized leaves have various advantages over fresh
materials such as long-term storage, increased antigen stability and content, and decreased
microbial contamination (Kwon et al., 2013b). After lyophilization, lettuce leaves showed a
22-fold increase in CTB-ESAT6 antigen content per gram compared with fresh leaves and
could be stored at room temperature for up to 6 months (Lakshmi et al., 2013). Freeze-dried
and stored materials preserve the integrity and immunogenicity of the heterologous fusion
protein, allowing efficient delivery to the GALT due to proper folding and assembly
(Boyhan and Daniell, 2011; Kwon et al., 2013b). However, HBsAg was not stable in
lyophilized lettuce leaves stored at room temperature, suggesting that the compartment or
level of an antigen’s expression may play a role in its stability (Czyż et al., 2014).
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Seeds offer several alternative subcellular destinations for recombinant proteins, including
PBs derived from the ER, PSVs, the surface of oil bodies and starch granules (Khan et al.,
2012). Seeds are also advantageous due to their ability to accumulate protein in a relatively
small volume and the high stability of the recombinant protein in dry seeds, allowing batch
processing and long-term storage (Peters and Stoger, 2011). Oral immunization with ricebased CTB stored at room temperature for more than 3 years still provided effective, longterm SIgA-mediated protection against CT- or LT-induced diarrhoea (Tokuhara et al.,
2010). Maize-derived HBsAg driven by the promoter of the cereal storage protein globulin1
showed high-level accumulation at a mean concentration of 0.51% TSP in T1 seeds. HBsAg
expressed in maize seeds was heat stable; it could tolerate temperatures of up to 55 °C for 1
month without degradation. Optimal heat stability was realized after oil extraction of ground
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maize material, either by SFE or hexane treatment (Hayden et al., 2012a). High levels of
HBsAg were obtained in maize grain, and SFE-treated maize material was formed into
edible wafers. Mice fed with wafers containing approximately 300 μg/g HBsAg showed
robust IgG and IgA responses in their sera (Hayden et al., 2014).
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Nonmammalian glycosylation and low recombinant protein yield are the two major
challenges against the full utilization of plants as alternative bioreactors instead of
mammalian cell culture. The challenge of choosing the most suitable host plant as an
expression system for biopharmaceuticals, as well as downstream processing, has also
received attention (Obembe et al., 2011). Glycosylation is the covalent linkage of sugar
molecules to proteins to improve their biological activity, folding, solubility and
immunogenicity (Arcalis et al., 2013). In plants, protein glycosylation occurs within the
secretory pathway in the ER and the Golgi complex. Plants attach core α(1,3)-linked fucose
and β(1,2)-linked xylose residues to the N-glycan of glycoproteins, whereas mammals add
α(1,6)-linked fucose, β(1,4)-linked galactose and sialic acid residues to the N-glycan
(Gomord et al., 2010). Hence, to prevent allergic reactions and immunogenicity when plantmade therapeutic animal proteins are delivered to humans, it is necessary to engineer the
host plant to perform authentic human N-glycosylation (Obembe et al., 2011). Plant-derived
recombinant human glycoproteins normally contain the carbohydrate groups α(1,3)fucose
and β(1,2)xylose, which are not found in mammals, and they lack the terminal galactose and
sialic acid residues that are required for the stability, activity and solubility of native human
glycoproteins (Gomord et al., 2010; Lico et al., 2012). Despite these challenges, the first
FDA approved plant-made biopharmaceutical is a glycoprotein, and so the limitations of
plant glycosylation did not cause any problems; indeed, the terminal mannose residues
facilitated the uptake of glucocerebrosidase by macrophages (Walsh, 2014).
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Because the chloroplast is an N-glycosylation-free compartment, it offers unique advantages
and disadvantages (Daniell et al., 2009). Because plant glycosylation is different from
human glycosylation, it requires careful modification of the glycosylation pathways to
resemble human glycoproteins as discussed above to avoid any unintended immune
responses. However, there are examples where glycosylation sites in human
biopharmaceuticals like IGF-1 are inactivated to obtain fully functional proteins (Hede et
al., 2012; Philippou and Barton, 2014). Chloroplasts are ideal to express such proteins
without glycosylation using the native sequence but are not suitable to express
glycoproteins.
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Mass spectrometry analyses demonstrated that all the N-glycosylation sites of the
extracellular domains of plant-based HA VLPs carry plant-specific complex or hybrid Nglycans having core α(1,3)-fucose and core β(1,2)-xylose epitopes and Lewisa extensions
(Le Mauff et al., 2014). No hypersensibility or induction of IgG or IgE directed against
these glycans of HA VLPs after immunization was observed in previous phase I and II
clinical studies (Landry et al., 2010). Furthermore, the identification of plant VLP raft
markers confirmed that the VLP formation mechanism in Nicotiana benthamiana is similar
to the natural process of influenza virus assembly in mammals (Le Mauff et al., 2014).
Plasmodium falciparum PfAMA1 consists of up to six recognition sites for N-linked
glycosylation, which are absent in P. falciparum. Glycosylated and nonglycosylated
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PfAMA1 accumulated to high levels in Nicotiana benthamiana after transient expression,
and the glycosylated variant was confirmed to contain high-mannose-type N-glycans.
Competition assays revealed that several epitopes were shielded from immune recognition
by the N-glycans. Thus, N-linked glycosylation may improve efficacy by enhancing
immunogenicity and/or focusing the response towards the corresponding epitopes by glycan
masking (Boes et al., 2015).
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The ability to avoid inflammatory responses to dietary and microbial antigens in the gut
mucosa is achieved by a mechanism termed oral tolerance (Oliveira et al., 2015). Repeated
oral immunization with large doses of the same antigen resulted in abrogated or decreased T
cell-mediated responses in animal models (Azizi et al., 2010). This phenomenon indicates
the possibility of mucosal tolerance induced by orally delivered vaccines. The dominant
target of oral tolerance for vaccine efficacy is the T-cell compartment, not the B cell
compartment. A number of studies have shown that the frequency of antigen administration
by the oral route is a critical factor for oral tolerance induction, indicating that multiple
feedings by gavage were more effective than a single feeding of antigen to induce oral
tolerance to inflammatory immune responses and autoimmune disease models (Guetard et
al., 2008; Oliveira et al., 2015; Wang et al., 2015). Continuous feeding correlates with the
enhanced production of TGF-β and IL-10, which are important mediators of oral tolerance
induction (Wang et al., 2013). Several factors affect oral tolerance induction, including age,
immunological status of the animal, dose and structure of the antigen, and the form of
antigen feeding (Oliveira et al., 2015). Indeed, oral delivery of several autoantigens
expressed in plant cells induced high levels of tolerance (Ruhlman et al., 2007; Sherman et
al., 2014; Verma et al., 2010; Wang et al., 2015).
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Tolerance versus immunity is not determined by fusion tags, but by the process of priming
with adjuvants. Although the molecular mechanism to distinguish participating subsets of
dendritic cells is not fully understood, the protocol is clearly reproducible with adjuvants via
injection conferring immunity (antibody production), whereas orally delivered antigens
induce tolerance (suppresses antibodies). Subcutaneous injection of the purified antigen with
a strong adjuvant assures presentation of the antigen in the context of a very strong
activation signal during priming. This sets up an immune response that is further boosted
orally. Therefore, the oral booster vaccine is effective when the systemic response has been
set up by priming with an adjuvant (Davoodi-Semiromi et al., 2010). The innate immune
receptor NLRP10 plays an important role in activation of dendritic cells by adjuvants
(Eisenbarth et al., 2012). In the presence of inflammatory stimuli (adjuvants), local DCs
become activated and present antigens for T-cell priming, locally and in the peripheral
lymphoid tissues where DCs can migrate. Immature DCs induce Tregs that affect DC
function and prevent stable DCs–effector T-cell contact, thereby priming the immune
response (Guetard et al., 2008). This is a very different scenario from the release of antigens
into the gut immune system without priming, which is geared towards an anti-inflammatory
response. The activation and maturation of DCs play a crucial role in the induction of
tolerance or immunity upon antigen delivery. When antigens are presented to T cells by
immature DCs in the absence of inflammation, they induce tolerance. Furthermore, by
secreting cytokines or by cell-to-cell contact, Tregs interfere with DC maturation, shifting
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DCs into tolerogenic function (Figure 1). Tregs begin suppressive effect by secretion of
cytokines IL-10 and TGF-β, which induce apoptosis or cell-cycle arrest in effector T cells
and block co-stimulation and maturation of dendritic cells. However, it has been
demonstrated there is no difference in the behaviour of CD4+ T cells during primary
exposure to antigen in priming or tolerizing conditions. Immune priming is associated with
the formation of large, stable clusters of CD4+ T cells around DCs, whereas during tolerance
induction, smaller, more short-lived clusters are formed. Subsequently, T cells return to
rapid migration, but this may take longer under conditions of priming than initiation of
tolerance (Shakhar et al., 2005; Zinselmeyer et al., 2005). These observations demonstrate
that altering the interaction between T cells and DCs can have profound consequences for
the induction of immunity. Therefore, the interaction between Tregs and DCs plays a major
role in orally delivered vaccine antigens bioencapsulated in plant cells.
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Thus, potential plant-based oral vaccines require suitable immunization protocols and
antigen formulations to ensure antigen stability through the alimentary tract and a balance
between immunity and oral tolerance, such as targeting pivotal APCs, co-administration
with a mucosal adjuvant for oral vaccine formulation, the optimization of oral antigen
delivery and its dosage and feeding frequency (Azegami et al., 2014; Pniewski et al., 2011;
Wang et al., 2013). Moreover, the temporal sequence of administration, with initial systemic
priming and mucosal boosting combined with the usage of certain adjuvants, is likely to
prevent mucosal tolerance induction (Azizi et al., 2010). These challenges should be
carefully addressed as this technology reaches clinical evaluation.
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An outline for the process of oral delivery of plant-derived vaccine antigens: (a) Foreign
genes are introduced and expressed in lettuce chloroplasts via particle bombardment. After
confirmation of stable integration of foreign genes into all of the chloroplast genomes in
each plant cell (achieving homoplasmy) and characterization of dosage and functionality,
transplastomic lines are transferred to the greenhouse to increase biomass. Harvested leaves
are lyophilized in programmed machines to maintain sublimation temperature below 20 °C,
powdered and stored in moisture-free environment. (b) Proposed mechanism of plantderived oral vaccines. Orally administered CTB-fused antigens are taken up by M cells
located in the FAE through the binding to GM1-ganglioside receptor. Antigens are then
captured by antigen-presenting cells, such as DCs, inducing antigen-specific T and B cells.
Th1-associated cytokines, such as IFN-γ, and Th2 cytokines, such as IL-4, IL-10, play
important roles in cell-mediated immunity and humoral immunity. Mucosal DCs induce
FoxP3+ Tregs via the production of TGF-β but that concomitant retinoic acid signalling
boosted this process. TGF-β mediates immune tolerance via induction and maintenance of
FoxP3+ Treg, which suppress Th1 and Th2 responses.
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Schematic representation of stable nuclear and chloroplast transformation processes. (a)
Gene(s) of interest (GOI) are introduced into plant chromosomes via Agrobacteriummediated transformation, followed by selection and regeneration. Phenotypic segregation of
the progeny via Mendelian inheritance is observed. (b) Chloroplast transformation using
particle gun bombardment of chloroplast vectors is followed by two to three rounds of
antibiotic selection and subsequent regeneration of homoplasmic transformants. GOI can be
engineered to express single or multiple genes. Transgene integration is mediated by sitespecific recombination, and maternal inheritance is shown in T1 progeny. P, promoter;
Marker, antibiotic selectable marker gene; T, terminator; LB, left border sequence; RB, right
border sequence; Cp, chloroplast; and RBS, ribosome-binding site.
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